An Anti-TRBC1 Antibody-Drug Conjugate Abrogates T-Cell Cancer Tumor Burden

Major Finding: Anti-TRBC1 chimeric antigen receptor T-cell activity is limited by fratricide by normal TRBC1⁺ T cells.

Concept: Development of an anti-TRBC1 antibody drug conjugate (ADC) demonstrates activity in T-cell cancers.

Impact: These results suggest that this anti-TRBC1 ADC could be an attractive therapeutic candidate for T-cell cancers.